Evidence map›Paper›PMID 34013255›Full record

ArticleResearch square2021

Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient.

Jon Klein, Anderson Brito, Paul Trubin, Peiwen Lu, Patrick Wong, Tara Alpert, Mario Pena-Hernandez, Winston Haynes, Kathy Kamath, Feimei Liu and 22 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 2 institutions in 2 countries.

Jon KleinYale University.ORCID 0000-0002-3552-7684
Anderson BritoYale.
Paul TrubinYale.
Peiwen LuYale.
Patrick WongYale University.
Tara AlpertYale School of Public Health.
Mario Pena-HernandezYale.
Winston HaynesSerimmune.
Kathy KamathSerimmune.
Feimei LiuYale University School of Medicine.ORCID 0000-0003-2663-6544
Chantal VogelsYale School of Public Health.ORCID 0000-0003-0027-6480
Joseph FauverYale University.ORCID 0000-0001-8099-2991
Carolina LucasYale University.ORCID 0000-0003-4590-2756
Ji Eun OhKorea Advanced Institute of Science and Technology.ORCID 0000-0003-2511-7064
Tianyang MaoYale University.ORCID 0000-0001-9251-8592
Julio SilvaYale School of Medicine.ORCID 0000-0001-8212-7440
Anne WyllieYale School of Public Health.ORCID 0000-0001-6015-0279
M Catherine MuenkerYale University.ORCID 0000-0002-0450-0868
Arnau Casanovas-MassanaYale University.ORCID 0000-0002-3301-6143
Adam MooreYale.
Mary PetroneYale School of Public Health.ORCID 0000-0002-3663-7535
Chaney KalinichYale School of Medicine.
YALE IMPACT RESEARCH TEAM
Charles Dela CruzYale University School of Medicine.ORCID 0000-0002-5258-1797
Shelli FarhadianYale University.ORCID 0000-0001-7230-1409
Aaron RingYale School of Medicine.ORCID 0000-0003-3699-2446
John ShonSerimmune (United States).
Albert KoYale School of Public Health.ORCID 0000-0001-9023-2339
Nathan GrubaughYale School of Public Health.ORCID 0000-0003-2031-1933
Benjamin Goldman-IsraelowYale University School of Medicine.ORCID 0000-0002-1308-8246
Akiko IwasakiYale University.ORCID 0000-0002-7824-9856
Yale University · USKorea Advanced Institute of Science and Technology · KR

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NRSA Training CoreTL1TR001864 · NCATS · YALE UNIVERSITY · PI CANTLEY, LLOYD G, EDELMAN, E. JENNIFER · 2016 to 2025
$9.9M
TRAINING IN THE PATHOGENESIS OF INFECTIOUS DISEASEST32AI007517 · NIAID · YALE UNIVERSITY · PI Jaimie Meyer, Albert C Shaw · 1997 to 2026
$6.1M
Short-Term Reserch Training: Students in Health SchoolsT35HL007649 · NHLBI · YALE UNIVERSITY · PI Sarwat I Chaudhry, Erica L Herzog · 1987 to 2026
$5.7M
NCATS NIH HHS TL1 TR001864NCATS NIH HHS UL1 TR001863NHLBI NIH HHS T35 HL007649NIAID NIH HHS T32 AI007517
6 · The paper itself

Abstract

The underlying immunologic deficiencies enabling SARS-CoV-2 reinfections are currently unknown. Here we describe a renal-transplant recipient who developed recurrent, symptomatic SARS-CoV-2 infection 7 months after primary infection. To elucidate the immunological mechanisms responsible for reinfection, we performed longitudinal profiling of cellular and humoral responses during both primary and recurrent SARS-CoV-2 infection. We found that the patient responded to the primary infection with transient, poor-quality adaptive immune responses that was further compromised by intervening treatment for acute rejection of the renal allograft prior to reinfection. Importantly, we identified the development of neutralizing antibodies and humoral memory responses prior to SARS-CoV-2 reinfection. However, these neutralizing antibodies failed to confer protection against reinfection, suggesting that additional factors are required for efficient prevention of SARS-CoV-2 reinfection. Further, we found no evidence supporting viral evasion of primary adaptive immune responses, suggesting that susceptibility to reinfection may be determined by host factors rather than pathogen adaptation.

Identifiers

PMID34013255
PMCPMC8132249
OpenAlexW3157052619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.